Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.70 |
| ▸ | CDK4 | P11802 | 14/20 | 0.70 |
| ▸ | CDK2 | P24941 | 13/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484150 | 0.83 | CDK4 (1.00) | GSK3BCDK4CDK2 | |
| Gw708336X SCHEMBL4463359 | 0.79 | CDK4 (1.00) | GSK3BCDK4CDK2KDR | |
| SCHEMBL5659235 | 0.79 | GSK3B (0.64) | GSK3BCDK4CDK2KDRSMG1 | |
| SCHEMBL4484482 | 0.76 | CDK4 (0.64) | GSK3BCDK4CDK2DYRK1A | |
| SCHEMBL4388675 | 0.76 | JAK2 (0.73) | CDK2PLK4CDK9 | |
| SCHEMBL2076215 | 0.72 | CDK2 (0.68) | GSK3BCDK4CDK2KDRPLK4 | |
| SCHEMBL4489702 | 0.70 | SLC2A1 (0.80) | GSK3BCDK4CDK2KDRCCNK | |
| SCHEMBL4485034 | 0.70 | GSK3B (0.82) | GSK3BCDK4CDK2KDRCCNK | |
| SCHEMBL4476755 | 0.70 | CDK4 (1.00) | GSK3BCDK4CDK2KDRDYRK1A | |
| SCHEMBL11919160 | 0.70 | KDR (0.48) | GSK3BCDK4CDK2KDRPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463730-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | claimed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | claimed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7279473-B2 | Pyrazolopyridazine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279473-B2 | Pyrazolopyridazine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1463730-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885CDK4 218/4885CDK2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.